Protagonist Therapeutics

$12.68
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.12 (0.96%) Today
$0.00 (0.00%) As of 4:00 PM EDT after-hours

Why Robinhood?

You can buy or sell PTGX and other stocks, options, ETFs, and crypto commission-free!

About PTGX

Protagonist Therapeutics, Inc. Common Stock, also called Protagonist Therapeutics, is a clinical-stage biopharmaceutical company, which engages in the research and development of novel constrained peptide-based drug candidates that address significant unmet medical needs. Read More The firm's initial lead product candidates, PTG-100 and PTG-200, are being developed for moderate-to-severe ulcerative colitis and Crohn's disease, respectively. The company was founded by Mark L. Smythe on August 22, 2006 and is headquartered in Newark, CA.

Employees
64
Headquarters
Newark, California
Founded
2006
Market Cap
333.23M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
260.93K
High Today
$13.05
Low Today
$12.40
Open Price
$12.57
Volume
600.47K
52 Week High
$14.36
52 Week Low
$5.49

Collections

PTGX Earnings

-$1.18
-$0.84
-$0.49
-$0.15
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Q3 2019
Estimated
Actual
Expected Nov 5, Pre-Market
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.